Tevogen Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in TVGN.
▼ -98.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $16.55 | $51.50 | $556.50 | $516.50 | |
| P/E | — | — | — | — | 281.2x |
| P/B | — | — | — | — | 4.8x |
| EPS | -$8.08 | -$3.50 | -$19.12 | $1.84 | |
| ROE | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FLNAFilana Therapeutics Inc | $0.93 | — | 0.7x | — | -55.78% | $44.88M |
| MGXMetagenomi Therapeutics, Inc. | $1.19 | — | 0.4x | — | -60.61% | $44.95M |
| GRCEGrace Therapeutics, Inc. | $2.12 | — | 0.7x | — | -36.19% | $44.6M |
| MLSSMilestone Scientific Inc | $0.50 |
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Company description provided by Yahoo Finance.
| — |
| 1.29% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 12.9x |
| — |
| -121.67% |
| $44.55M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |
| QTIQt Imaging Holdings Inc | $3.09 | — | 19.0x | — | -2125.30% | $45.23M |